China A roundup of some of the biggest pharma and biotech news from China including the collaboration between Elektr and Sinopharm; Biocytogen’s partnership with Janssen and deal with Chipscreen Biosciences; China’s first personalised neoantigen-targeted cancer vaccine approval; the final green light for Sino Biopharm’s purchase of F-star, and AstraZeneca’s deal with…
UAE A roundup of the latest pharma news from the United Arab Emirates (UAE) including Julpher’s pursuit of its growth strategy with a new CEO, Global Pharma’s tech transfer deal with Egypt’s Nerhado and Pharma Solutions’ procurement of its first thalassemia generic. AstraZeneca announces move to Dubai Science Park with…
China In light of ongoing geopolitical tension, a globally unfavourable macroeconomic environment and new drug-pricing legislation in the US, at the recent BIO CEO and Investor Conference industry stakeholders evaluated the risks and the opportunities for cross-border deal-making between US and China and found a number of reasons to be optimistic.…
Brazil The latest from Brazilian Pharma, including the controversial proposal to transform Brazil’s regulatory agency, ANVISA; Ease Labs’s canabidiol approval, Biolab’s international expansion ambitions and Eurofarma’s multiple myeloma deal. ANVISA’s autonomy challenged by Congress (Regulatory Focus) After the swearing in Brazilian’s President Luiz Inácio Lula da Silva earlier this year,…
Greece Nicos Ragoussis explains how he steered the Greek affiliate of Danish dermatology specialist LEO Pharma through the unprecedented challenges of the government-debt crisis era, the ongoing market access hurdles that still remain, and why he is highly optimistic about future business prospects. The hard times are behind us and…
Poland Poland’s largest pharmaceutical company and leading generics manufacturer, Polpharma, is looking to expand its presence outside of the country’s borders. With a recent acquisition bid for former Sanofi European generics unit, Zentiva, Polpharma is building on a growing international footprint beyond its CEE base. Founded over 80 years ago,…
Global With the global market for generic drugs expected to reach USD 36.4 billion by 2027 and grow at a CAGR of 5.6 percent over the period 2020-2027, it is not surprising that a number of generics producers continue to rank among the world’s top pharma companies. A look at the…
CEE Some of the most important stories emanating from the Central and Eastern European (CEE) region’s pharma industry, including Polpharma’s bid for Zentiva, Richter’s acquisition of OC Distributors and MDD approval in the US, Hungary’s windfall tax on pharma, Presage’s collaboration with Pure Biologics and Lithuania’s biotech ambitions. Polpharma working…
Egypt Barely four and a half years ago, Egyptian President Abdel Fattah el-Sisi secured overwhelming re-election vowing to “place public health front and centre” of a radical reform and stabilization agenda. What has occurred subsequently has undoubtedly been momentous. Firstly, his administration unveiled ambitious plans to provide universal, cradle to grave,…
USA Initial public offerings (IPOs) —a vital source of cash for up-and-coming biotechs— saw a huge decline in 2022 with respect to the previous year. After 2021’s record of more than 100 biotech IPOs that raised almost USD 15 billion in funds, 2022 saw a mere 17 biotechnology companies launch IPOs…
India The latest news from the Indian pharma industry, including WHO’s recommendation not to use cough syrup from Marion Biotech after further deaths, Indegene’s expanded presence in Europe, Sun Pharma’s FDA warning and the lab partnership between Sai Life Sciences and Schrödinger. WHO recommends not using Marion Biotech cough syrups…
Africa Diabetes is a significant, and growing, problem in Africa, making access to insulin products a regional imperative. Some important progress is being made, including a new deal between US giant Eli Lilly and Egyptian group EVA Pharma. The agreement will allow Lilly products to be manufactured in, and for, the…
See our Cookie Privacy Policy Here